Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of CAPRELSA is substantial. |
Clinical Added Value
| minor |
The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
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
0rLechW2sv3gBHSU
